Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Aug 2021, 16:37.
Patrick Lin - 05 Aug 2021 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 05 Aug 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2021, 16:37:01 UTC
- Prior SEC filing
- 09 Jul 2021
- Next SEC filing
- 30 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 09 Aug 2021.
Change
- Previous filing in this sequence was filed on 09 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Award
- Transaction value
- Shares
- +7,601
- Change %
- +1.8%
- Price
- Shares after
- 418,890
- Date
- 05 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Vesting of time-based restricted shares.